Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
- PMID: 25660991
- DOI: 10.1136/annrheumdis-2014-206439
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
Abstract
Objective: To prospectively analyse the risk for disease relapses in patients with rheumatoid arthritis (RA) in sustained remission, either continuing, tapering or stopping disease-modifying antirheumatic drugs (DMARDs) in a prospective randomised controlled trial.
Methods: Reduction of Therapy in patients with Rheumatoid arthritis in Ongoing remission is a multicentre, randomised controlled, parallel-group phase 3 trial evaluating the effects of tapering and stopping all conventional and/or biological DMARDs in patients with RA in stable remission. Patients (disease activity score 28 (DAS28)<2.6 for least 6 months) were randomised into three arms, either continuing DMARDs (arm 1), tapering DMARDs by 50% (arm 2) or stopping DMARDs after 6 months tapering (arm 3). The primary endpoint was sustained remission during 12 months.
Results: In this interim analysis, the first 101 patients who completed the study were analysed. At baseline, all patients fulfilled DAS28 remission and 70% also American College of Rheumatology- European League Against Rheumatism Boolean remission. 82.2% of the patients received methotrexate, 40.6% biological DMARDs and 9.9% other DMARDs. Overall, 67 patients (66.3%) remained in remission for 12 months, whereas 34 patients (33.7%) relapsed. The incidence of relapses was related to study arms (p=0.007; arm 1: 15.8%; arm 2: 38.9%; arm 3: 51.9%). Multivariate logistic regression identified anticitrullinated protein antibodies (ACPA) positivity (p=0.038) and treatment reduction (in comparison to continuation) as predictors for relapse (arm 2: p=0.012; arm 3: p=0.003).
Conclusions: This randomised controlled study testing three different treatment strategies in patients with RA in sustained remission demonstrated that more than half of the patients maintain in remission after tapering or stopping conventional and biological DMARD treatment. Relapses occurred particularly in the first 6 months after treatment reduction and were associated with the presence of ACPA.
Trial registration number: 2009-015740-42.
Keywords: DMARDs (biologic); DMARDs (synthetic); Disease Activity; Rheumatoid Arthritis; Treatment.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.Ann Rheum Dis. 2016 Sep;75(9):1637-44. doi: 10.1136/annrheumdis-2015-207900. Epub 2015 Oct 19. Ann Rheum Dis. 2016. PMID: 26483255 Free PMC article. Clinical Trial.
-
Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.Clin Rheumatol. 2016 Dec;35(12):2915-2923. doi: 10.1007/s10067-016-3413-8. Epub 2016 Sep 22. Clin Rheumatol. 2016. PMID: 27658417 Clinical Trial.
-
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.Lancet Rheumatol. 2024 May;6(5):e268-e278. doi: 10.1016/S2665-9913(24)00021-3. Epub 2024 Apr 4. Lancet Rheumatol. 2024. PMID: 38583450 Clinical Trial.
-
Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.J Rheumatol. 2015 Nov;42(11):2012-22. doi: 10.3899/jrheum.141520. Epub 2015 Oct 1. J Rheumatol. 2015. PMID: 26428204 Review.
-
[Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].Rev Med Interne. 2017 Apr;38(4):256-263. doi: 10.1016/j.revmed.2016.12.014. Epub 2017 Feb 1. Rev Med Interne. 2017. PMID: 28161110 Review. French.
Cited by
-
Tapering csDMARD or TNFi first: is the risk of flares different for ACPA-positive or ACPA-negative rheumatoid arthritis?RMD Open. 2024 Jul 20;10(3):e004258. doi: 10.1136/rmdopen-2024-004258. RMD Open. 2024. PMID: 39032947 Free PMC article. No abstract available.
-
Predicting Flare in Patients With Rheumatoid Arthritis in Biologic Induced Remission, on Tapering, and on Stable Therapy.ACR Open Rheumatol. 2024 May;6(5):294-303. doi: 10.1002/acr2.11656. Epub 2024 Feb 27. ACR Open Rheumatol. 2024. PMID: 38411023 Free PMC article.
-
Innate immune memory in inflammatory arthritis.Nat Rev Rheumatol. 2023 Oct;19(10):627-639. doi: 10.1038/s41584-023-01009-0. Epub 2023 Sep 6. Nat Rev Rheumatol. 2023. PMID: 37674048 Review.
-
Efficacy and safety of curcumin in maintaining remission during disease-modifying antirheumatic drug withdrawal in rheumatoid arthritis at 52 weeks: a phase III double-blind, randomized placebo-controlled trial.Rheumatol Int. 2023 Dec;43(12):2193-2200. doi: 10.1007/s00296-023-05417-z. Epub 2023 Aug 31. Rheumatol Int. 2023. PMID: 37650921
-
A large-scale Boolean model of the rheumatoid arthritis fibroblast-like synoviocytes predicts drug synergies in the arthritic joint.NPJ Syst Biol Appl. 2023 Jul 15;9(1):33. doi: 10.1038/s41540-023-00294-5. NPJ Syst Biol Appl. 2023. PMID: 37454172 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical